Investor Presentaiton

Brief Profile BUSINESS OVERVIEW o Integrated CDMO company with strong capabilities right from process research & development to late stage clinical and commercial manufacturing. KEY STRENGTHS 。 Preferred global outsourcing partner with capabilities across the entire CDMO value chain. • Strong chemistry skills. FINANCIAL OVERVIEW 。 Standalone Revenues, EBITDA and Adj. PAT of Rs 3541 Mn, Rs 1799 Mn and Rs 1243 Mn in Q1-FY24. o Strong balance sheet with D:E ratio of less than 0.02 as on Jun-23. SUVEN 14 PHARMA

View entire presentation